Cochrane · systematic review · CD007443
Probiotics for maintenance of remission in ulcerative colitis
Iheozor-Ejiofor, Z, Kaur, L, Gordon, M, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
11
No studies
5
Included studies
NR
No studies 5 · 27.8%Ungraded 2 · 11.1%Very low 6 · 33.3%Low 5 · 27.8%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsProbiotics compared to placebo for maintenance of remission in ulcerative colitis
Population: people with ulcerative colitis in remission
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical relapse (12 to 52 weeks) Probiotics vs placebo | RR 0.87 [0.63, 1.18] | 4 studies · 361 participants | Very low Downgraded: imprecision |
Maintenance of clinical remission (52 weeks) Probiotics vs placebo | RR 1.16 [0.98, 1.37] | 2 studies · 141 participants | Very low Downgraded: imprecision |
Serious adverse events (48 to 52 weeks) Probiotics vs placebo | no estimate extracted | 4 studies · 351 participants | Ungraded |
Withdrawal due to adverse events Probiotics vs placebo | no estimate extracted | 2 studies · 113 participants | Ungraded |
Need for additional therapy Probiotics vs placebo | no estimate extracted | NR | No studies |
Health‐related quality of life (12 weeks) Probiotics vs placebo | no estimate extracted | 1 study · 25 participants | Low Downgraded: imprecision |
Probiotics compared to 5‐aminosalicylic acid (5‐ASA) (mesalazine) for maintenance of remission in ulcerative colitis
Population: people with ulcerative colitis in remission
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical relapse (52 weeks) Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) | RR 1.01 [0.84, 1.22] | 2 studies · 452 participants | Low Downgraded: risk of bias, imprecision |
Maintenance of clinical remission (52 weeks) Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) | RR 1.06 [0.9, 1.25] | 1 study · 125 participants | Low Downgraded: risk of bias, imprecision |
Serious adverse events (52 weeks) Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) | RR 1.19 [0.41, 3.46] | 1 study · 327 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawal due to adverse events (52 weeks) Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) | RR 1.02 [0.46, 2.25] | 1 study · 222 participants | Very low Downgraded: risk of bias, imprecision |
Need for additional therapy Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) | no estimate extracted | NR | No studies |
Health‐related quality of life (52 weeks) Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) | no estimate extracted | 1 study · 222 participants | Low Downgraded: risk of bias, imprecision |
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) compared to 5‐ASA (mesalazine) for maintenance of remission in ulcerative colitis
Population: people with ulcerative colitis in remission
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical relapse (12 to 52 weeks) Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐ASA (mesalazine) | RR 1.11 [0.66, 1.87] | 2 studies · 242 participants | Very low Downgraded: risk of bias, imprecision |
Maintenance of clinical remission (24 to 52 weeks) Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐ASA (mesalazine) | RR 1.05 [0.89, 1.24] | 1 study · 122 participants | Low Downgraded: risk of bias, imprecision |
Serious adverse events Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐ASA (mesalazine) | no estimate extracted | NR | No studies |
Withdrawal due to adverse events (12 to 52 weeks) Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐ASA (mesalazine) | RR 5.29 [0.26, 107.63] | 2 studies · 127 participants | Very low Downgraded: risk of bias, imprecision |
Need for additional therapy Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐ASA (mesalazine) | no estimate extracted | NR | No studies |
Health‐related quality of life Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐ASA (mesalazine) | no estimate extracted | NR | No studies |